LeMaitre Vascular
LMAT
261 hedge funds and large institutions have $1.69B invested in LeMaitre Vascular in 2024 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 92 increasing their positions, 97 reducing their positions, and 25 closing their positions.
300% more call options, than puts
Call options by funds: $296K | Put options by funds: $74K
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
80% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 25
26% more capital invested
Capital invested by funds: $1.34B → $1.69B (+$344M)
7% more funds holding
Funds holding: 243 → 261 (+18)
0.7% more ownership
Funds ownership: 90.75% → 91.45% (+0.7%)
5% less repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 97
Top Buyers
Top Sellers
LMAT Hedge Fund Activity: Q2 2024 in Review
261 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in LeMaitre Vascular (LMAT) for Q2 2024, worth a combined $1.69B — up 26% from $1.34B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new LMAT positions and 25 closed out — a net gain of 20 holders — while 92 added to existing stakes and 97 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $20.1M. The largest seller was Copeland Capital Management, cutting an estimated $10.2M.
- 261 institutional investors held LeMaitre Vascular (LMAT) as of Q2 2024, up from 243 in Q1 2024.
- Funds reported $1.69B of LeMaitre Vascular stock for Q2 2024, up 26% quarter-over-quarter.
- 45 funds opened new LeMaitre Vascular positions in Q2 2024 and 25 closed out, a net change of +20 holders.
- The largest LeMaitre Vascular buyer in Q2 2024 was T. Rowe Price Associates, an estimated $20.1M added.
- The largest LeMaitre Vascular seller in Q2 2024 was Copeland Capital Management, an estimated $10.2M sold.
Based on aggregated 13F filings for Q2 2024.